top of page


  • Writer's pictureBrooks Hill Partners

Brooks Hill Partners Invests in Totient

Brooks Hill Partners has announced an investment in Totient, a Boston-based startup that uses advanced immunoinformatics, ML and AI, and immunological research into tertiary lymphoid structures to select and assemble monoclonal antibodies expressed in tissues affected by autoimmunity, infections, and cancer.

UPDATE: Totient was acquired by Absci in Jun. 2021

Brooks Hill Partners is a life sciences consultancy and early-stage health tech venture capital firm that partners with passionate companies across the biopharma and healthcare landscape. Please contact us to learn more about how we can help you today. For more information, visit and follow us on LinkedIn.  


Interested in learning more?

Are you a health tech founder?

bottom of page